A team at Massachusetts General Hospital and Harvard Medical School has developed an artificial intelligence–based method to screen currently available medications as possible treatments for Alzheimer’s disease.
- People of diverse ancestry have typically been excluded from genome-wide association studies, exacerbating existing health disparities.
- A free-access software package called Tractor allows genetics researchers to account for ancestry in a precise manner. This advance will improve the discovery of gene variants that increase risk of disease in both understudied individuals and the population as a whole.
Elizabeth Atkinson, PhD,
We can get more powerful and precise genetic association signals and do a better job at pinpointing where the causal mutation is, which improves our understanding of disease for everyone.
Analytic and Translational Genetics Unit, Massachusetts General Hospital
BOSTON -- Genome-wide association studies (GWAS) have typically excluded diverse and minority individuals in the search for gene variants that confer risk of disease. Researchers at Massachusetts General Hospital (MGH), the Broad Institute of MIT and Harvard, and other institutions around the world have now developed a free-access software package called Tractor that increases the discovery power of genomics in understudied populations. A study of Tractor’s performance and accuracy was published in Nature Genetics.
Researchers perform GWAS to identify where genetic variants responsible for causing disease are located in the genome. Recently, geneticists have begun creating models from published GWAS data to predict risks of disease in individuals. But the clinical utility of these models is currently limited, since most are based on genomic studies of people with European ancestry.
“If you build disease-risk models on available data and attempt to extrapolate them to diverse populations, the accuracy of predicting who will get sick is reduced,” says Elizabeth Atkinson, PhD, lead author of the paper and an investigator in the Analytic and Translational Genetics Unit (ATGU) at MGH. “These errors exacerbate existing health disparities, in part because we aren’t finding specific gene variants that may contribute to higher risk of a particular disease in diverse populations.”
Another significant shortcoming of current GWAS is that “they leave many opportunities for genetic discovery on the table for all populations,” says Atkinson. People of African descent, for example, have a million more genetic variations on average than someone who doesn’t have African ancestry due to human migration patterns over the ages. Conducting a GWAS with diverse populations allows geneticists to pinpoint genetic associations to disease at many more spots across the genome, says Atkinson.
“Within these genomic regions identified in a GWAS, the genetic mutation that actually causes disease is shared across ancestries most of the time,” she adds. By studying admixed populations — people with recent ancestry from two or more previously isolated population groups, such as Africa and Europe — “we can get more powerful and precise genetic association signals and do a better job at pinpointing where the causal mutation is, which improves our understanding of disease for everyone.”
Until now, there was no fine-scale way to control for ancestry composition in mixed groups being studied in a GWAS. “Different ancestry groups have gene variants that occur at different frequencies due to the populations’ demographic history,” explains Atkinson. “Not taking ancestry into account in a GWAS can lead to false-positive hits or to gene variants cancelling themselves out and dismissed as not important. So, until now, it’s been easier to exclude people with multiple ancestries from GWAS to avoid being confounded by different patterns of gene variants.”
Tractor, however, allows researchers to account for ancestry in a precise manner so admixed individuals can be included in large-scale gene discovery efforts. The software colors pieces of each person’s chromosomes according to its ancestry origin, which researchers can infer from reference genome sequences, and uses this information in a new GWAS model. “Tractor takes into account the ancestry backbone of each genetic variant so we can correctly calibrate the GWAS results to find causal variants in specific population groups,” says Atkinson.
Tractor also provides estimates of ancestry-specific effect sizes, which isn’t possible in a standard GWAS. “Instead of getting a weighted average of the disease-risk effect size for a particular gene variant, Tractor can determine how large or small the effect of a variant is in various ancestry groups,” says Atkinson. “This will be informative for building genetic risk scores in diverse populations.” Another advantage of Tractor is its ability to improve the power of GWAS by detecting risk gene variants across multiple ancestries. “With Tractor, we can get stronger disease-association signals by leveraging ancestral genomic differences,” says Atkinson.
“Tractor advances the existing methodologies for studying the genetics of complex disorders in diverse and minority populations,” she adds. “We hope that this method increases the inclusion of admixed participants in large-scale association studies going forward.”
Major funding for this study was provided by the National Institute of Mental Health.
Co-authors include Mark Daly, PhD, founding chief of the ATGU and associate professor of Medicine at Harvard Medical School (HMS); and Benjamin Neale, PhD, also of the ATGU, is associate professor of Medicine at HMS and director of Population Genetics, Stanley Center for Psychiatric Research, at the Broad Institute.
About the Massachusetts General Hospital
Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of "America’s Best Hospitals."
- Press Release
- Mar | 3 | 2021
These reactions should not discourage patients from getting the vaccine, researchers say.
- Press Release
- Mar | 2 | 2021
Experts offer guidance to reduce false positive tests and avoid unnecessary biopsies.
- Press Release
- Feb | 26 | 2021
Two new models boost accuracy in assessing which COVID-19 patients face the greatest risk of mechanical ventilation and death
A pair of novel calculators could help hospitals predict patient outcomes and better allocate scarce resources such as ICU beds and ventilators.
- Press Release
- Feb | 24 | 2021
Radiologists offer an approach to avoid confusion among patients and clinicians.
- Press Release
- Feb | 23 | 2021
The Healey Center at MGH and the Northeast ALS (NEALS) Consortium launched the first platform trial for amyotrophic lateral sclerosis (ALS), in which multiple treatments are tested and evaluated simultaneously to accelerate the development of therapies for people with ALS.